About Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.
CEO
Junheng Xie
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Price Target
About Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $352.02K ▲ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▼ |
| Q1-2025 | $0 | $413.41K ▲ | $184.66K ▼ | 0% | $0.02 ▼ | $184.66K ▼ |
| Q4-2024 | $0 | $402.02K ▲ | $444.11K ▼ | 0% | $0.05 ▼ | $444.11K ▼ |
| Q3-2024 | $0 | $200.02K | $743.51K | 0% | $0.08 | $743.51K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K ▼ | $43.6M ▼ | $2.38M ▲ | $41.23M ▼ |
| Q4-2024 | $28.21K ▼ | $73.81M ▲ | $1.51M ▲ | $72.31M ▲ |
| Q3-2024 | $103.56K | $72.78M | $920.79K | $71.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K ▼ | $-224.01K ▼ | $30.79M ▲ | $-30.58M ▼ | $-20.86K ▲ | $-224.01K ▼ |
| Q4-2024 | $444.11K ▼ | $-195.13K ▼ | $-277.7K ▼ | $397.48K ▲ | $-75.35K ▼ | $-195.13K ▼ |
| Q3-2024 | $743.51K | $-53.95K | $0 | $0 | $-53.95K | $-53.95K |
CEO
Junheng Xie
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+